松弛素治疗心力衰竭的研究进展  

Research progress of relaxin in treatment of heart failure

作　　者：戎成振[1] 卢家忠[1] RONG Cheng-zhen, LU Jia-zhong(Department of Cardiology, Fuyang Second People＇s Hospital, Fuyang 236000, Anhui, Chin)

机构地区：[1]阜阳市第二人民医院心内科,安徽阜阳236000

出　　处：《心脏杂志》2018年第3期368-371,共4页Chinese Heart Journal

摘　　要：心力衰竭是一种复杂的临床综合征,血管功能紊乱是导致心力衰竭(HF)的原因之一,松弛素(serelaxin,relaxin-2)是一种重组血管活性肽,导致全身和肾血管舒张,是治疗急性HF的一种药物。松弛素治疗HF的临床效益可归因于改善循环系统,心脏和肾脏血流动力学、保护细胞和器官免受损害,具有抗炎,抗重构、抗纤维化、抗心肌缺血和促血管生成的影响,可减少心脏和肾缺血缺氧状态,降低HF死亡率。本文重点介绍松弛素的作用机制以及在HF治疗中的临床试验。Heart failure is a complex clinical syndrome and vascular dysfunction is one of the leading causes of heart failure. Relaxin is a human relaxin （ serelaxin, relaxin-2） recombinant vasoactive peptide for systemic and renal vasodilation, and is one of the pharmacological treatments of acute heart failure. The clinical benefits of relaxin in the treatment of congestive heart failure can be attributed to improvement in the circulatory system, the heart, renal hemodynamies, protection of cells and organs from damage, effects of anti-inflammation, anti-impact, anti-fibrotic remodeling and anti-myocardial ischemia, promotion of angiogenesis, reduction of heart and kidney ischemia and hypoxia, and decrease of heart failure mortality. In this review, we focus on the role of relaxin and its mechanism and review clinical trials of relaxin in treatment of heart failure.

关 键 词：松弛素 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]